uniQure N.V. top oder flop!?
https://www.uniqure.com/investors-media/press-releases
strategische Reorganisation
- 20% der Gesamtbelegschaft soll abgebaut werden
- Investitionen in mehr als die Hälfte seiner Forschungs- und Technologieprojekte sollen eingestellt werden (inkl. AMT-210 bei Parkinson)
- durch die Umstrukturierung erwartet QURE in den nächsten 3 Jahren Einsparungen in Höhe von 180 Mio. $
https://www.fiercebiotech.com/biotech/...p-gene-therapies-clinic-2027
MK 321 Mio. $ deutlich unter Cash.
https://www.uniqure.com/programs-pipeline/pipeline
Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024
~ Announced FDA clearance of two Investigational New Drug (IND) applications; Initiation of Phase I/II clinical trials in mesial temporal lobe epilepsy (mTLE) and Fabry disease, in addition to SOD1-ALS, are expected in the first half of 2024
Announced strategic reorganization to advance multiple clinical-stage programs and deliver $180 million of cost savings over the next three years
238 Mio. $ MK vs. 618 Mio. $ Cash (bis Q2/27)